We and others have previously described a number of characteristics that are associated with delays in diagnosis and increased risk for inadequate treatment of older women and men with cancer. These characteristics include poor social support, limited access to transportation, and impaired cognition. However, there is little information on how these factors influence survival of older cancer patients. Purpose: The purpose of the study was to determine which patient characteristics predicted survival up to 10 years after the diagnosis of cancer. 
nosis and inadequate treatment of older cancer patients are associated with poor survival. Impaired cognition and inadequate education in elderly patients are also associated with poor survival. This decreased survival does not appear to be a consequence of known barriers to health care that are responsible for delays in diagnosis and for inadequate treatment. Implications: Efforts to facilitate early diagnosis and receipt of definitive treatment for cancer in older individuals may improve their survival. [J Natl Cancer Inst 1996;88:
1031-8]
The average age of cancer patients in the United States has increased steadily throughout this century, driven by the rise in the proportion of elderly within the population and the steep increase with age in the incidence of most cancers. More than half of all cancers are now diagnosed in individuals aged 65 years and older (/) , yet most of what we know about the diagnosis and treatment of cancer originates from studies in younger populations (2) . The medical community has become increasingly aware that the appropriate medical care of older patients requires attention to factors not routinely considered in the treatment of younger patients (3) . For example, for older cancer patients, social support, access to transportation, and cognitive status may influence delay in diagnosis or the adequacy of treatment {4-6). Advanced age places patients at risk for undertreatment, even after controlling for such factors as comorbidity, cognitive status, social support, and functional status (5, 7, 8) .
In 1984, we initiated a population-based study of 799 men and women aged 65 years or older, newly diagnosed with cancer and living in a six-county area in New Mexico, to better understand the factors that influence stage at diagnosis and choice of treatment in the elderly (5,9-7/) . We have previously reported on the factors affecting stage at diagnosis (9, 10) and choice of treatment (5) for those subjects. We found that receipt of regular medical care, good knowledge about cancer, and good functional status all were associated with a higher likelihood of diagnosis of cancer at a local stage (10) . Younger patients (i.e., those aged 65-75 years versus those >75 years), cognitively intact patients, and those with good access to transportation were more likely to receive treatments that would usually be considered to be appropriate (5) . We now report on the predictors of survival of these patients up to 10 years following diagnosis.
Methods Case Selection
Subjects were ascertained through the New Mexico Tumor Registry, which provides population-based coverage of all newly diagnosed cancer cases, other than nonmelanoma skin cancer, in residents of New Mexico {12). Cases picked up at postmortem examination or by death certificate were excluded. The New Mexico Tumor Registry is a member of the Surveillance, Epidemiology, and End Results (SEER) Program 1 of the National Cancer Institute. Persons selected for interview met the following criteria: 65 or more years of age; resident of Bernalillo, Sandoval, Cibola, Valencia, Dona Ana, or Santa Fe County at the time of the recent diagnosis; race other than American Indian; and diagnosed between May 15, 1984, and May 15, 1986, with cancer of the colon, rectum, breast, uterus, uterine cervix, prostate, thyroid, or buccal cavity or with malignant melanoma. The cancer sites were selected on the basis of previous analyses of the relationship between age and stage at diagnosis (13) and on the basis of availability of screening tests or effective therapy. All diagnoses were made on the basis of positive histologic examination of tissue, except for four cases of prostate cancer, one of which was diagnosed by exfoliative cytology, two by radiology, and one clinically.
During the 2-year enrollment period, 1054 subjects met the eligibility criteria for this investigation. The physician refused to give consent for 67 subjects, and consent was not obtained for some other reason for 39. Of the 948 subjects or next of kin approached, completed interviews were obtained from 799. We encountered 94 refusals; 28 subjects or their next of kin were unavailable for interview; and 27 subjects were not interviewed for some other reason. Interviews were obtained more often for females than for males (79.8% versus 72.4%) and for non-Hispanic whites than for Hispanics (77.6% versus 71.0%). The mean age of the 799 interviewed subjects was 72.2 years, with no difference among sites, whereas that for the noninterviewed subjects was 73.8 years.
This investigation was approved by the University of New Mexico Institutional Review Board, in accordance with an assurance filed with and approved by the U.S. Department of Health and Human Services.
Data Collection
After physician consent was obtained, subjects or their next of kin were interviewed in person in their homes. All interviewers were bilingual, and the interview was conducted in Spanish for 32 of the 799 subjects. Next of kin were interviewed if the index subject was deceased (n = 53) or mentally incompetent (n = 60); the remainder were interviewed directly (n = 686). The determination of whether the subject was mentally competent to be interviewed was made by a global impression of the interviewer and the next of kin. To assess the validity of the information obtained from the next of kin interviews, we obtained information on selected items on social support networks and functional status from the next of kin for all subjects (14) . There was good agreement between the answers from the subjects and the surrogates on most items. For example, the kappa values for the presence of other medical conditions ranged from 0.40 to 0.84. with a mean value of 0.57. There was no evidence of bias in the surrogates' responses and no effect of the subject's age or cognitive status on level of agreement (14) .
The standardized questionnaire obtained demographic data and detailed information on presenting symptoms and on patient and physician delay (9) . Most of the questions in the standardized questionnaire were referenced to the year before the development of symptoms related to the present cancer. For subjects who reported no symptoms related to their cancer, the year before diagnosis by a physician was used as the reference period. The year before diagnosis also was used for subjects who had had symptoms longer than 2 years before diagnosis.
For the reference year, we assessed the living situation, social support, activity level, functional status, access to transportation, health status, insurance coverage, use of health care services, and health practices (//). The subjects also completed a brief mental status examination.
Patient delay was calculated as the number of weeks between symptom onset and a visit to a physician for those symptoms (9) . The total physical activity score was computed by first assigning scores of 0-6 for 17 specific activities on the basis of the frequency that each was performed during the reference year (e.g., cooking, housework, grocery shopping, gardening, swimming, and calisthenics). A score of 0 was assigned for a frequency of less than once a month, a score of 6 for daily; scores of 1 -5 were assigned for intermediate frequencies.
Scores of 6 for full-time employment, 4 for part-time employment, and 0 for not employed were also assigned. The individual scores were summed to form the total activity score. The total activity score ranged from 0 through 57, with a median of 22. The 20th percentile was 14.
The social support network index was based on that described by Berkman and Syme (15) and used procedures provided by Schoenbach (16) to compute the index. The social support index combines information about the frequency of contact and the number of close friends, children, grandchildren, siblings, and other relatives living in the vicinity. The index also includes information on marital status and activity in church and clubs. In our sample, the social support index ranged from 1 through 12, with a mean of 5. The 25th percentile was 2.
Functional status, the ability of the individual to function independently in a variety of areas, was assessed by the method of Katz and Akpom (17) . The index counts the number of the following activities that the respondent required help with during the reference year: bathing, dressing, going to the bathroom, getting in or out of bed or a chair, and feeding himself or herself.
The brief mental status test was abridged from that of Jacobs et al. (18) and assessed orientation, knowledge, judgment, and short-term memory. It contained nine items and was similar to that used in The Established Populations for Epidemiologic Studies of the Elderly in East Boston, MA, New Haven, CT, and rural Iowa (19) . Subjects were also asked the name of their condition and asked four true-false questions about cancer (e.g., "There are many different types of cancer, some more serious than others"). Subjects with correct responses to all four questions were categorized as having good knowledge.
Comorbidity was determined by a checklist of 11 common medical conditions. Subjects who responded that they saw a physician in the year prior to cancer diagnosis for any of those conditions and that the condition limited their activity during the year were classified as having medical comorbidity.
Stage at Diagnosis
We classified stage of disease at diagnosis into four categories: 1) in situ (noninvasive), 2) local (invasive cancer confined to the organ of ongin), 3) regional (spread to adjacent organs by direct extension or to regional lymph nodes), and 4) distant (extension to organs other than those covered in the regional category or metastases to distant organs or distant lymph nodes) (1320).
Therapy for Cancer
All information concerning site, stage, and treatment of cancer was obtained from the registry files. We developed lists of definitive therapies for local and regional stage cancers of major sites and have previously reported the percentages of patients receiving less than definitive treatments (5). For local or regional breast cancer, the nondefinitive treatments were lumpectomy without radiotherapy (n = 10), simple mastectomy without radiotherapy (n = 5), and no breast surgery or radiation after excisional biopsy (n = 8). Locally advanced inoperable cancers were excluded from the analyses. For local or regional prostate cancer, the nondefinitive treatments were no treatment following biopsy (n = 26) and transurethral prostatectomy alone (n = 1). For local or regional colorectal cancer, the nondefinitive treatment was no surgery following diagnosis (n = 6).
Follow-up
For each case, the New Mexico Tumor Registry updates the last known date of follow-up and the vital status, usually on the basis of information requested annually from the patient's primary physician. Of subjects not known to be dead, median follow-up was 102 months, with a range of 28-119 months. Only three subjects had a follow-up of less than 80 months, hi addition to follow-up information from the subject's primary physician, the registry also matches against regional and national databases of death certificates. The cutoff date for followup was May 31, 1994 . For the 646 cases considered in this report, 396 (61%) were known to be dead as of May 31, 1994 .
Statistical Methods
Cases with unknown stage (n = 16) at diagnosis or with three or more primary cancers (n = 7) were omitted from the analyses. For the analyses in this report, we considered only the 646 patients with cancer of the breast (n = 188), prostate (n = 247), and colon or rectum (n = 211). The remaining sites had too few cases for analytic purposes.
The survival function was estimated by the Kaplan-Meier product-limit method, and the standard errors of the estimates were determined by Greenwood's formula (21) . We computed survival time as the number of days between the date of diagnosis and the date of the last follow-up or death. Case subjects who were not known to be dead were censored at the date of the last follow-up. Actual survival at a tune t is defined as the proportion of subjects surviving from diagnosis until time I. We estimated actual survival using the product-limit method. Relative survival at time t is defined as the ratio of the actual survival at time t to the predicted survival from a standard population with the same age, gender, and ethnic group distribution. We used 1980 survival tables for the U.S. population as our standard (22) . The association of specific patient characteristics with survival was first assessed in bivariate models adjusted for age, gender, and cancer site. Multivariate survival models were then developed with the use of the proportional hazards technique as implemented by the SAS procedure PHREG (SAS Institute, Inc., Cary, NC) (25) . All models had terms for age at diagnosis (to nearest year) and gender (if appropriate). The effect of age in the analytic models was linear. The analyses including all three cancer sites used stratified P-H models, with the site of cancer forming the strata. Cancers with an unknown stage at diagnosis (n = 7) were omitted from the multivariate analyses. For the multivariate models presented in Tables 3 and  4 , we entered the factors that were significantly predictive in the bivariate analyses (Table 2) . We also kept ethnicity in the model to assess its effect independent of income, education, and social support, to which it is closely correlated. The number of subjects with missing data on any characteristic is given in Table 2 . We used two dummy variables in the analyses to account for the missing data: one for those subjects who had died in the approximate 2-month period between diagnosis of cancer and the interview (n = 39) and one for those who were incompetent (n = 47). In both cases, information was obtained by proxy interview, which resulted in missing data for some characteristics (e.g., knowledge about cancer).
Results Table 1 presents the actual and relative (age-adjusted) survival for men and women aged 65 years and older with cancer of the breast, colon or rectum, or prostate. The relative survival of the patients with prostate cancer stabilized after 4 years, while for colorectal cancer, the relative survival stabilized after 6 years. Relative survival of breast cancer patients continued to fall throughout the 8 years of follow-up. Table 2 presents the age-, gender-, and site-adjusted effects on patient survival of several patient characteristics. Measures of health status, such as the presence of other medical diagnoses (comorbidity), functional status, and level of physical activity, all predicted survival. Socioeconomic status, assessed by income and educational level, had an impact of similar magnitude on survival. Cognitive status was strongly predictive of overall survival. Type of treatment (definitive or other) had a large effect, with those not receiving definitive treatment having a more than threefold greater death rate. Availability of social support also predicted survival, while patient ethnicity, delay in diagnosis, and presence of a primary care physician did not have significant effects. Table 3 presents three multivariate models that assess the effects of patient characteristics on survival. For these analyses, all factors showing a significant effect in Table 2 in addition to ethnicity were entered into the survival model; the resulting hazards ratios estimate the effect of each characteristic on patient survival, independent of other characteristics included in the models. The first model includes all patient characteristics, but excludes stage at diagnosis or type of treatment (definitive versus nondefinitive). The second model adds stage at diagnosis and the third model contains those variables and the type of treatment received. Model 1 addresses which patient characteristics independently influenced survival, while the second and third models indicate the extent to which the effect of a patient characteristic on survival is explained by stage at diagnosis or choice of treatment (definitive versus nondefinitive). 'Actual survival at a time t is defined as the proportion of subjects surviving after diagnosis until time t. fRelative survival at a time / is defined as the ratio of actual survival at time I to the predicted survival from a standard population with same age, gender, and ethnic group distribution. Comparing the hazards ratios in Table 2 with those in Model 1 of Table 3 , the effects of education and cognitive status were virtually unchanged in the multivariate analysis, while the effects of income, social support, access to transportation, comorbidity, functional status, and physical activity were reduced or eliminated.
The factors considered in Table 3 could have an impact survival through a number of pathways, including influencing the stage of the cancer at diagnosis or the type of treatment given. The effects of education and cognitive status were essentially unchanged after adding the stage of diagnosis (Model 2) and the type of treatment (Model 3) to the analyses, suggesting that these variables do not affect survival by pathways including either stage or treatment. Receipt of treatment considered definitive was still a predictor of survival, after controlling for stage at diagnosis, socioeconomic factors, comorbidity, and physical functioning (Model 3), although the hazards ratio decreased from 3.3 with control for age and site (Table 2 ) to 1.6 in the full multivariate model. In stratified analyses, we found no evidence for an interaction between cognitive status and either stage at diagnosis or type of treatment on survival (data not shown).
The analyses in Tables 2 and 3 represent grouped data from patients with breast, prostate, and colorectal cancers. In analyses of each cancer separately, the hazard ratios associated with various patient characteristics were similar to the grouped data, although the smaller numbers produced wider confidence intervals ( Table 4 ). The one exception was the risk of death associated with not receiving definitive treatment. Patients with prostate cancer who did not receive definitive treatment had no greater risk of death than those who received definitive treatment, while for both breast and colorectal cancers, nondefinite treatment predicted significantly increased risk of death (Table  4) .
Discussion
Over the past decade, a number of studies from various parts of the United States have found that some older men and women who were diagnosed with cancer have not received therapy that is considered definitive or usually appropriate {5-824-26). The undertreatment cannot be adequately explained by comorbidity; that is, older cancer patients with no other medical illnesses and no functional impairment are still less likely to receive definitive treatments than are younger patients (5, 7) . Indeed, nonclinical factors, such as ethnicity (27) (28) (29) , marital status (4), access to transportation (5), place of residence (6^4 JO), and educational status (<5), seem to have at least as large an influence on type of therapy for the elderly as do clinical factors.
What are the reasons for this undertreatment of the older cancer patient? A major contribution might be physician uncertainty as to the best treatment for an older man or woman with cancer. Physicians, in general, are poorly informed about basic concepts of aging (31) . Sources of information are scant; in the past, older people were rarely included in controlled trials of therapies for cancer or other diseases, although this may be changing (2J2). Thus, the clinician must extrapolate from the findings of studies in younger patients, and such extrapolation may not always be appropriate. For example, one might question whether 5-and 10-year survival data generated on younger patients are relevant to decisions about therapy in a 75-year-old man whose average life expectancy without cancer is less than 10 years. Also, while the potential benefit in terms of absolute years of life saved declines with age, the toxicity of some cancer treatments increases in the elderly (33) . For frail elderly patients, apparent undertreatment might actually represent appropriate clinical decision making (34) . In this regard, our finding that type of treatment has an impact on survival is evidence that what we (526) and others (6-8J.425) have termed "less than appropriate therapy" is indeed less than appropriate; it is associated with a more than twofold higher death rate in older patients with breast or colorectal cancer. Others (35) have recently reported a similar twofold higher death rate in those receiving less than appropriate therapy for breast cancer, but comorbidity and other patient characteristics could not be measured in that study. In the present analyses, we controlled for comorbidity and general markers of physical "frailty" such as functional status and level of physical activity. For some cancer sites, older patients have poorer relative (ageadjusted) survival than do younger ones (36) . Our data would suggest that the practice of providing some older cancer patients with less than definitive care may be contributing to the poor survival in this group.
A similar point can be made about stage at diagnosis and survival. Satariano (37) has recently questioned the wisdom of screening for breast cancer in women with substantial comorbidity. This is based on his finding that in women with three or more comorbid conditions, stage at diagnosis is not related to survival (38) . Our findings should sound a cautionary note against any increase in diagnostic or therapeutic nihilism in most older patients. Stage at diagnosis and choice of treatment are the major remediable determinants of survival of older patients with breast or colorectal cancer (Table 4) .
It is interesting to note that, in distinction to patients with breast and colorectal cancer, type of treatment had no influence on survival of older men with prostate cancer. This is consistent with other reports (39) (40) (41) that have questioned whether radical prostatectomy, the "definitive" and "usually appropriate" treatment for early stage prostate cancer, confers any survival advantage. This question is becoming more critical because the widespread marketing of various forms of prostate cancer screening by medical and lay organizations can be expected to increase the diagnosis of prostate cancer and use of a radical surgery of questionable effectiveness (42) .
The results of this study must be interpreted in the context of potential limitations of the study design. These interview-based data are potentially limited by the accuracy of information that can be obtained from elderly subjects by interview (43) . In particular, our assessment of comorbidity was limited to self-report of illness. It could be argued that the surgeons were appropriately choosing "nondefinitive" treatments for frail elderly patients unable to tolerate more aggressive therapy and that our comorbidity measure was not sufficiently sensitive to pick up such frailty. On the other hand, we did include separate measures of functional status and physical activity, which taken together with comorbidity, should control for the important but ill-defined concept of physical frailty in the analyses. In addition, it is not clear that these results found in a population-based sample of elderly New Mexicans are generalizable to other areas of the country; specifically, the Hispanic population of New Mexico is different from that of surrounding states in its degree of acculturation and residence over many generations. Another limitation of this study is the relatively small number of subjects studied and the small proportion of them receiving nondefinitive treatment. This precaution is strongest in the case of colorectal cancer, where only six of the 211 subjects received nondefinitive treatment; in contrast, 23 (12%) of the 188 women with breast cancer received less than definitive treatment.
There is extensive literature on the positive and independent effect of educational status on survival in the general population as well as in patient groups with specific diseases (44) (45) (46) . Less extensive, but equally convincing, data show that cognitive dysfunction also affects survival (47, 48) . The mechanisms responsible for these associations are unknown, but speculation has included the hypothesis that poor education or poor cognition might be disadvantageous in dealing with the demands of modern life, such as obtaining appropriate medical care. Alternatively, some (49$0) have argued that the effect of education on health cannot be explained by differences in access to care but is best viewed as a correlate of psychologic issues. Surprisingly, the strong effects of education and cognitive status on survival in our population (Table 2) were independent of medical access issues, such as stage of diagnosis or type of treatment, and were not reduced by controlling for level of social support (Table 3) . Thus, while our findings confirm the importance of education and cognitive status on survival, the data do not resolve the question of how these effects are mediated.
In large population-based studies, poor social support would appear to be a risk factor for cancer mortality independent of health-related behaviors and other factors (4$1). These observations have stimulated a growing interest in psychosocial interventions for cancer patients (52) . We found no independent effect of social support on survival in this population of older cancer patients. This finding agrees with that of Cassileth et al. (55) , who also reported no effect of social support on survival in their study of 359 cancer patients. However, neither the present study nor that of Cassileth et al. (55) had sufficient power to detect the relatively modest (approximately 25%) increases in mortality associated with poor social support found in the larger studies (4$1).
We have previously reported that Hispanics in New Mexico have higher mortality from most cancers than non-Hispanic whites, but that the increased mortality can be explained entirely by stage at diagnosis and treatment patterns (29) . We now extend those findings by showing that after control of additional factors, Hispanics actually experience better survival. This finding is consistent with other recent reports (54J>5) suggesting that while major barriers in access to health care exist for some Hispanic populations, the general health of this population as measured by birth outcomes or by death rates from major diseases compares favorably with the non-Hispanic white population.
In summary, education, cognitive status, and ethnicity independently influence survival in older cancer patients, with patients judged incompetent experiencing a threefold higher death rate after controlling for stage at diagnosis, choice of treatment, and other factors. Stage at diagnosis and choice of treatment also clearly affect survival. Thus, the importance of early diagnosis and the appropriate treatment of cancer does not diminish with age, but these factors do not explain the decreased survival associated with cognitive impairment.
